Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis
Abstract Background Breast cancer is one of the most common malignancies in women worldwide, and one of the leading causes of cancer-related death. Programmed cell death 1 (PD-1) and its ligand (PD-L1) are key physiologic suppressors of the cytotoxic immune reaction. Some authors advocate that PD-L1...
Main Authors: | Isnard Elman Litvin, Machline Paim Paganella, Eliana Marcia Wendland, Adriana Vial Roehe |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-03-01
|
Series: | Systematic Reviews |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13643-020-01306-9 |
Similar Items
-
Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
by: Long Ma, et al.
Published: (2021-08-01) -
Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
by: Yafang Huang, et al.
Published: (2019-05-01) -
Safety and efficacy of Momordica charantia Linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol
by: Emanuel L. Peter, et al.
Published: (2018-11-01) -
Prognostic Role of PD-1 and PD-L1 Expression in Gastric Cancer Patients: A Meta-analysis
by: WANG Yufeng, et al.
Published: (2020-05-01) -
Is a fusobacterium nucleatum infection in the colon a risk factor for colorectal cancer?: a systematic review and meta-analysis protocol
by: Amal Idrissi Janati, et al.
Published: (2019-05-01)